PL2470168T3 - Sposoby zapobiegania i leczenia niedokrwienia mózgu - Google Patents

Sposoby zapobiegania i leczenia niedokrwienia mózgu

Info

Publication number
PL2470168T3
PL2470168T3 PL10747777T PL10747777T PL2470168T3 PL 2470168 T3 PL2470168 T3 PL 2470168T3 PL 10747777 T PL10747777 T PL 10747777T PL 10747777 T PL10747777 T PL 10747777T PL 2470168 T3 PL2470168 T3 PL 2470168T3
Authority
PL
Poland
Prior art keywords
prevention
treatment
methods
cerebral ischemia
ischemia
Prior art date
Application number
PL10747777T
Other languages
English (en)
Polish (pl)
Inventor
Guy M. Miller
Viktoria Kheifets
Original Assignee
Bioelectron Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Technology Corporation filed Critical Bioelectron Technology Corporation
Publication of PL2470168T3 publication Critical patent/PL2470168T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10747777T 2009-08-26 2010-08-24 Sposoby zapobiegania i leczenia niedokrwienia mózgu PL2470168T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27526909P 2009-08-26 2009-08-26
EP10747777.0A EP2470168B1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia
PCT/US2010/046503 WO2011025785A1 (en) 2009-08-26 2010-08-24 Methods for the prevention and treatment of cerebral ischemia

Publications (1)

Publication Number Publication Date
PL2470168T3 true PL2470168T3 (pl) 2018-06-29

Family

ID=42983642

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10747777T PL2470168T3 (pl) 2009-08-26 2010-08-24 Sposoby zapobiegania i leczenia niedokrwienia mózgu

Country Status (17)

Country Link
US (3) US20110207828A1 (enExample)
EP (1) EP2470168B1 (enExample)
JP (2) JP5785546B2 (enExample)
CN (1) CN102647981B (enExample)
AU (1) AU2010286704B2 (enExample)
BR (1) BR112012004167A2 (enExample)
CA (1) CA2772294C (enExample)
DK (1) DK2470168T3 (enExample)
EA (1) EA028677B1 (enExample)
ES (1) ES2663709T3 (enExample)
HU (1) HUE037592T2 (enExample)
MX (1) MX337990B (enExample)
NO (1) NO2470168T3 (enExample)
PL (1) PL2470168T3 (enExample)
PT (1) PT2470168T (enExample)
SI (1) SI2470168T1 (enExample)
WO (1) WO2011025785A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005032544A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
ES2714900T3 (es) 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
SI3456707T1 (sl) 2007-11-06 2020-10-30 Ptc Therapeutics, Inc. Derivati 4-(P-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijske bolezni
WO2009089224A1 (en) * 2008-01-08 2009-07-16 Edison Pharmaceuticals, Inc. (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
JP5710277B2 (ja) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体
JP5798481B2 (ja) 2008-06-25 2015-10-21 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体
JP2012502064A (ja) 2008-09-10 2012-01-26 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化還元活性治療剤を用いての広汎性発達障害の処置
WO2010045220A1 (en) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
MY157119A (en) 2008-10-28 2016-05-13 Edison Pharmaceuticals Inc Process for the production of alpha-tocotrienol and derivatives
HUE037574T2 (hu) 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
CA2797644A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
SI2680873T1 (sl) 2011-03-03 2017-12-29 Cidara Therapeutics, Inc. Protiglivna sredstva in njihova uporaba
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
GB201117808D0 (en) * 2011-10-14 2011-11-30 Siemens Medical Solutions SUV correction following dose infiltration
PL3677252T3 (pl) * 2012-03-19 2024-01-08 Cidara Therapeutics, Inc. Schematy dawkowania dla związków z klasy echinokandyn
CA2883882A1 (en) * 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Benzoquinone derivatives for treating oxidative stress disorders
CN112451518B (zh) * 2012-11-13 2025-02-21 因维克特斯生物技术有限公司 生育三烯酚的经粘膜递送
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
CA2906145A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
RU2578451C1 (ru) * 2014-12-09 2016-03-27 Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях
WO2016100579A1 (en) 2014-12-16 2016-06-23 Edison Pharmaceuticals, Inc., Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
JP7117241B2 (ja) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス， インコーポレイテッド 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
ES2955711T3 (es) 2016-03-16 2023-12-05 Cidara Therapeutics Inc Regímenes de dosificación para el tratamiento de infecciones fúngicas
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
CN111050798A (zh) 2017-07-12 2020-04-21 奇达拉治疗公司 用于治疗真菌感染的组合物和方法
MX2021000157A (es) * 2018-07-03 2021-12-10 Venturis Therapeutics Inc Composiciones y métodos para tratar el derrame cerebral.
KR102337954B1 (ko) * 2018-08-16 2021-12-10 차의과학대학교 산학협력단 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법
FI3866772T3 (fi) 2018-10-17 2024-01-11 Ptc Therapeutics Inc 2,3,5-trimetyyli-6-nonyylisykloheksa-2,5-dieeni-1,4-dioni alfa-synukleinopatioiden, tauopatioiden ja muiden häiriöiden estämiseen ja hoitoon
CA3156499A1 (en) 2019-10-04 2021-04-08 Stealth Biotherapeutics Inc. CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS
JP2022552002A (ja) * 2019-10-17 2022-12-14 ザ・ペン・ステイト・リサーチ・ファウンデイション 出血性脳卒中の治療のための機能的ニューロンの再生
EP4126836A1 (en) 2020-04-03 2023-02-08 Stealth BioTherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia
CN116762096A (zh) * 2020-12-22 2023-09-15 皇家飞利浦有限公司 定位血管收缩
CN113066113B (zh) * 2021-04-27 2022-01-11 河北医科大学第二医院 自发性高血压大鼠脑模板和地图集的构建方法及设备
CN118175991A (zh) 2021-07-08 2024-06-11 Ptc医疗公司 包含2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮的药物组合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5938203B2 (ja) * 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US5872108A (en) * 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
US6232060B1 (en) * 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) * 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
FR2753098B1 (fr) * 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
EP1037628A4 (en) 1997-11-17 2002-08-21 Lipogenics Inc METHOD FOR PREVENTING RESTENOSE USING TOCOTRIENOLE
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) * 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6346544B2 (en) * 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
DE10034233A1 (de) * 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
US20020132845A1 (en) * 2000-12-15 2002-09-19 Miller Guy Michael Compositions and methods for the prevention and treatment of tissue ischemia
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
MXPA04001555A (es) * 2001-08-21 2004-10-27 Galileo Pharmaceuticals Inc Composiciones enriquecidas con tocoferol y mejoramiento de sintomas inflamatorios.
WO2003043570A2 (en) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US20040152764A1 (en) * 2001-12-14 2004-08-05 Miller Guy M. Compositions and methods for the prevention and treatment of cerebral ischemia
US6653346B1 (en) * 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) * 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
EP1558922B1 (en) * 2002-10-30 2013-02-27 Ampere Life Sciences, Inc. Identifying therapeutic compounds based on their physical-chemical properties
WO2005032544A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Treatment of mitochondrial diseases
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
ES2714900T3 (es) * 2005-06-01 2019-05-30 Bioelectron Tech Corp Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP2101808A4 (en) * 2007-01-10 2011-11-30 Edison Pharmaceuticals Inc TREATMENT OF BREATHLY TROUBLES USING COMPOUNDS OF ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY
SI3456707T1 (sl) * 2007-11-06 2020-10-30 Ptc Therapeutics, Inc. Derivati 4-(P-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijske bolezni
EP2242506A4 (en) * 2008-01-07 2011-12-28 Janssen Biotech Inc METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS
WO2009089224A1 (en) * 2008-01-08 2009-07-16 Edison Pharmaceuticals, Inc. (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
WO2009111543A2 (en) * 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
JP5710277B2 (ja) * 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体
WO2009140382A2 (en) * 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
EP2303309A2 (en) * 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
JP5798481B2 (ja) * 2008-06-25 2015-10-21 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体
WO2010005989A1 (en) * 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) * 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
JP2012502064A (ja) * 2008-09-10 2012-01-26 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化還元活性治療剤を用いての広汎性発達障害の処置
WO2010045220A1 (en) * 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
MY157119A (en) * 2008-10-28 2016-05-13 Edison Pharmaceuticals Inc Process for the production of alpha-tocotrienol and derivatives
HUE037574T2 (hu) * 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
US20100273892A1 (en) * 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
JP2012525398A (ja) * 2009-04-28 2012-10-22 アンペア ライフ サイエンシーズ，インコーポレイテッド 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用
EP2609921A1 (en) * 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
CA2797644A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011126998A1 (en) * 2010-04-06 2011-10-13 Edison Pharmaceuticals, Inc. Treatment of ataxia telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) * 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
US20120295985A1 (en) * 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control

Also Published As

Publication number Publication date
CN102647981A (zh) 2012-08-22
US20170007553A1 (en) 2017-01-12
EA028677B1 (ru) 2017-12-29
BR112012004167A2 (pt) 2016-03-29
PT2470168T (pt) 2018-03-28
JP2013503168A (ja) 2013-01-31
MX337990B (es) 2016-03-30
CN102647981B (zh) 2016-09-28
EP2470168B1 (en) 2018-01-31
SI2470168T1 (en) 2018-05-31
AU2010286704A1 (en) 2012-03-22
CA2772294C (en) 2018-08-21
NO2470168T3 (enExample) 2018-06-30
MX2012002374A (es) 2012-04-10
CA2772294A1 (en) 2011-03-03
HUE037592T2 (hu) 2018-09-28
EP2470168A1 (en) 2012-07-04
EA201200355A1 (ru) 2012-07-30
US20110207828A1 (en) 2011-08-25
US20180344667A1 (en) 2018-12-06
DK2470168T3 (en) 2018-05-07
JP5785546B2 (ja) 2015-09-30
WO2011025785A1 (en) 2011-03-03
ES2663709T3 (es) 2018-04-16
AU2010286704B2 (en) 2016-10-20
JP2015091899A (ja) 2015-05-14

Similar Documents

Publication Publication Date Title
PT2470168T (pt) Métodos para a prevenção e o tratamento de isquemia cerebral
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
EP2552433A4 (en) COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
EP2493309A4 (en) METHODS OF TREATING OR PREVENTING ACUTE ERYTHEMA
IL253293B (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
GB0915515D0 (en) Treatment of vasculoproliferative conditions
GB0919097D0 (en) Treatment of hard surfaces
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
ZA201300954B (en) Methods for treating and/or reversing neurodegenerative deseases and/or disorders
SG11201504542PA (en) Probiotic strains for the treatment and/or prevention of diarrhœa
PT2731616E (pt) Método para a prevenção e tratamento da sépsis
IL215990A0 (en) Phosphotetrahydfropyran compounds for the treatment of wounds and fibrotic disorders
IL238126A0 (en) Compositions for the treatment and prevention of obesity
PL2731584T3 (pl) Zastosowanie związków oligosacharydowych do zapobiegania i leczenia patologicznych blizn
PL2493305T3 (pl) Związki 2-aminoindolowe i sposoby leczenia malarii
EP2559432A4 (en) MEANS FOR THE PREVENTION AND TREATMENT OF ACUTE AND CHRONIC PANCREATITIS
SI2451287T1 (sl) Sestavki in postopek za preprečevanje in zdravljenje ognjevke
IL223219A0 (en) Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies
EP2459507A4 (en) USE OF ERYTHRITOL FOR THE PREVENTION OR TREATMENT OF HYPERTONIA
EP2467375A4 (en) FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF
AP3019A (en) Use of ferroquine in the treatment or prevention of malaria
ZA201005770B (en) The treatment of damaged skin
HU0800012D0 (en) Novel use and methods for the treatment and prevention of ulcerative colitis